Last week, NACDS took issue with an op-ed in The Wall Street Journal titled, “In Defense of Pharmacy Benefit Managers (PBMs),” which asserted that “swarms of drug-company lobbyists appear to have united both parties in opposition to [PBMs]” and that PBMs – unreasonably – “are taking the blame for high drug prices.”
With only 25 in-district work days left in July and August, the pharmacy community continues its great work promoting pro-patient, pro-pharmacy policy priorities to Members of Congress and their staff via the NACDS RxIMPACT Pharmacy Tour Program.
On July 8, Florida Governor Ron DeSantis issued an Executive Order “to drive transparency in prescription costs for Floridians.
NACDS’ engagement on national issues of critical importance to the industry and the patients it serves continues to generate awareness among the broader national trade association community.
The Federal Trade Commission’s (FTC) unanimous decision this week to examine pharmacy benefit manager (PBM) issues contributes to a growing wave of attention and action that stands to protect patients’ healthcare access and affordability and the viability of pharmacies of diverse sizes and formats.
In May, NACDS Foundation Chairman and NACDS President and CEO Steven C. Anderson was recognized as a 2022 Regional Honoree at the Alzheimer’s Association Brain Ball in Washington, DC.
The Future of Pharmacy Care Coalition, of which NACDS serves on the Executive Committee, continues to aggressively advocate and build support for the Equitable Community Access to Pharmacist Services Act (HR 7213) — bipartisan legislation that would help ensure the continuity of accessible pharmacy-based care, during public health emergencies and every day.
NACDS continues to urge collaboration across the Biden Administration and the U.S. Congress to help ensure allocation of funding for the Health Resources and Services Administration (HRSA) Uninsured Program, Coverage Assistance Fund (CAF) Program, testing programs and other essential COVID-19 care programs for COVID-19 vaccinations, testing and treatment.
Dr. Adalja described the AMA’s position on COVID-19 antivirals as a “surefire path to ensuring that the window for timely treatment only opens a crack, at best.”
On Wednesday, March 2, the Oversight and Investigations Subcommittee of the U.S. House of Representatives Energy and Commerce Committee held a hearing titled, “Lessons from the Frontline: COVID-19’s Impact on American Health Care.”
